Dose-finding designs: the role of convergence properties.
It is common for novel dose-finding designs to be presented without a study of their convergence properties. In this article we suggest that examination of convergence is a necessary quality check for dose-finding designs. We present a new convergence proof for a nonparametric family of methods called "interval designs," under certain conditions on the toxicity-frequency function F. We compare these conditions with the convergence conditions for the popular CRM one-parameter Phase I cancer design, via an innovative numerical sensitivity study generating a diverse sample of dose-toxicity scenarios. Only a small fraction of scenarios meet the Shen-O'Quigley convergence conditions for CRM. Conditions for "interval design" convergence are met more often, but still less than half the time. In the discussion, we illustrate how convergence properties and limitations help provide insight about small-sample behavior.
University of Washington, USA.
Assaf P
AP
Oron
David
D
Azriel
Peter D
PD
Hoff
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D054796:Drug Dosage Calculations; D006801:Humans; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents